FierceBiotech Radio: #FierceMadness and a peek into the drug-naming process

drug names bracket FPMK
Be sure to download a bracket, fill it out and tweet it @FierceBiotech and @FiercePharma to get in on the fun!

FierceBiotech's Amirah Al Idrus sits down with FiercePharma's Carly Helfand and Beth Snyder Bulik to discuss this year's #FierceMadness drug-name tournament. Which names are strong contenders? Which names evoke unappealing images? And, ultimately, which name will be the last one standing?

We also chat with Scott Piergrossi, vice president of creative development at Brand Institute, a branding and identity development company that worked on more than 80% of the drug names the FDA approved in 2017.

Check out the #FierceMadness matchups and download a bracket here. And download the episode on iTunes or Stitcher, or listen below—and be sure to subscribe. Let us know what you think by leaving a review or dropping us a line at [email protected].


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.


Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.